Drug Profile
CpG 8916
Latest Information Update: 02 Jul 2023
Price :
$50
*
At a glance
- Originator Coley Pharmaceutical Group
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 13 Aug 2001 This agent is still in active development
- 23 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
- 03 Jul 2000 Coley Pharmaceutical has established a CRADA with the Ludwig Institute